This study demonstrated that lornoxicam administered as a quick-release formulation is not inferior to the equivalent formulation of diclofenac potassium in terms of onset of PAR in patients ...

GlaxoSmithKline recently developed a novel technology for the formulation of modified-release tablets. The authors describe the route from development to commercialization. There are a number of ...

Numerous therapeutic advantages are offered by sustained-release drugs, which release active pharmaceutical ingredients (APIs) in a gradual manner. However, the QC of such drugs through conventional ...

Research examined the effects of varying excipient and polymer weight in coatings designed to optimize the release of diclofenac sodium. The goal was to release it at night to improve the treatment of ...

Background: NSAIDs are widely used for patients presenting with low back pain. A quick-release formulation of lornoxicam, a potent NSAID from the chemical class of oxicams, offers a faster onset of ...